[Skip to Content]
[Skip to Content Landing]
Views 4,657
Citations 0
Biotech Innovations
November 13, 2018

Relapses After CAR-T Therapy

JAMA. 2018;320(18):1850. doi:10.1001/jama.2018.17585

A case study recently published in Nature Medicine describes a rare mechanism of fatal relapse following chimeric antigen receptor T cell (CAR-T) therapy.

Researchers at the University of Pennsylvania (Penn)—where CAR-T therapies against cancer were first developed—reported that a 20-year-old male patient with B–cell acute lymphoblastic leukemia began to relapse 9 months after receiving the treatment as part of a phase 1 trial of the then-investigational agent CTL019 (tisagenlecleucel, now marketed by Novartis as Kymriah).